Gonadorelin

Origin and Structure

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. Native GnRH was isolated and sequenced in 1971 by Andrew Schally and independently by Roger Guillemin, work that earned them the 1977 Nobel Prize in Physiology or Medicine. It is produced by a small population of hypothalamic neurons and released in pulses into the hypothalamic-pituitary portal system.

Synthetic gonadorelin has been available as a pharmaceutical for decades under brand names including Factrel (FDA-approved 1982 for diagnostic use) and Lutrepulse (approved 1990 for pulsatile therapy of hypothalamic amenorrhea). It is structurally identical to endogenous GnRH — not a modified analogue — which makes it distinct from the long-acting GnRH agonists used in oncology.

Mechanism of Action

Gonadorelin binds the GnRH receptor on pituitary gonadotrophs, stimulating release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The biological response is exquisitely sensitive to the pattern of exposure:

• Pulsatile administration — mimicking the native physiological rhythm of roughly one pulse every 60–120 minutes — maintains and supports gonadotropin secretion and downstream testosterone or estrogen production.
• Continuous or long-acting administration rapidly downregulates the GnRH receptor and produces a state of pharmacological hypogonadism. This is the principle behind GnRH-agonist oncology drugs (see triptorelin and nafarelin), which use the same receptor to achieve the opposite clinical effect.

Because native gonadorelin has a circulating half-life of only 2–4 minutes, it does not produce the sustained suppression seen with analogues. This short duration is simultaneously a limitation (requires frequent dosing) and a feature (allows pulsatile protocols).

Clinical Evidence

Gonadorelin has three established clinical roles:

• Diagnostic testing. The GnRH stimulation test (single IV bolus, LH/FSH measured at intervals) distinguishes hypothalamic from pituitary causes of hypogonadism and is used in evaluating delayed or precocious puberty.
• Pulsatile treatment of hypothalamic amenorrhea and male hypogonadotropic hypogonadism, historically delivered via a programmable pump.
• Off-label adjunct to testosterone replacement therapy (TRT). This has become the most common contemporary use outside specialist endocrinology. Intermittent subcutaneous gonadorelin is used in place of hCG to maintain intratesticular testosterone, testicular volume, and spermatogenesis in men on exogenous testosterone. Community and clinic protocols vary widely, and head-to-head gonadorelin-versus-hCG trials in this specific use case are limited.

Practical Considerations

Common TRT-adjunct protocols use 50–200 mcg subcutaneously two to three times per week, sometimes more frequently. Because the half-life is short, any attempt to replicate native pulsatility with a few injections per week is a significant simplification of the physiology — clinicians using this approach typically report sufficient testicular support for their patients, but this remains pragmatic dosing rather than physiologically optimal dosing.

Gonadorelin differs fundamentally from kisspeptin, which acts upstream of GnRH neurons, and from the long-acting GnRH agonists used in oncology. A user choosing between these three is choosing among three different levels of the HPG axis.

Safety and Regulatory Status

Gonadorelin is FDA-approved and has a long safety record. Reported side effects are mild — injection-site reaction, transient flushing, occasional headache or nausea. Hypersensitivity reactions are rare. Unlike the long-acting analogues, gonadorelin does not cause the bone-density loss associated with chronic hypogonadism, because it does not suppress the axis.

Compounded gonadorelin for TRT-adjunct use is available from US compounding pharmacies with a prescription. Gray-market research-chemical supply also exists and carries the usual purity and sterility caveats. It is prohibited in-competition by WADA when used to manipulate endogenous hormone production.

The Bottom Line

Gonadorelin is native GnRH — an established, FDA-approved peptide with a clear physiological role. Its resurgence through TRT-adjunct use is more pharmacologically sensible than many peptide trends, though formal head-to-head data against hCG in that specific niche is still catching up with clinical practice.